Circulating Tumor Cell Detection Predicts Early Metastatic Relapse After Neoadjuvant Chemotherapy in Large Operable and Locally Advanced Breast Cancer in a Phase II Randomized Trial
暂无分享,去创建一个
Anne Vincent-Salomon | Patricia de Cremoux | A. Vincent-Salomon | M. Marty | F. Bidard | J. Pierga | P. de Cremoux | S. Delaloge | E. Brain | C. Mathiot | S. Giachetti | Etienne Brain | Suzette Delaloge | Jean-Yves Pierga | R. Salmon | Michel Marty | Claire Mathiot | François-Clément Bidard | Sylvie Giachetti | Rémy Salmon | P. de Crémoux
[1] G. T. Budd,et al. Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival , 2006, Clinical Cancer Research.
[2] P. Hurteloup,et al. Inflammatory Breast Cancer: Pilot Study of Intensive Induction Chemotherapy (FEC‐HD) Results in a High Histologic Response Rate , 1993 .
[3] J. Nesland,et al. A European interlaboratory testing of three well‐known procedures for immunocytochemical detection of epithelial cells in bone marrow. Results from analysis of normal bone marrow , 2006, Cytometry. Part B, Clinical cytometry.
[4] Jonathan W. Uhr,et al. Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases , 2004, Clinical Cancer Research.
[5] M. Rezai,et al. Circulating tumor cells (CTCs) in peripheral blood of primary breast cancer patients , 2007 .
[6] R. Bast,et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Brigitte Rack,et al. Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the CellSearch System , 2007, Clinical Cancer Research.
[8] T. Powles,et al. Good clinical response of breast cancers to neoadjuvant chemoendocrine therapy is associated with improved overall survival. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] Kristine R Broglio,et al. Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden. , 2007, Clinical breast cancer.
[10] A. Vincent-Salomon,et al. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer , 2000, British Journal of Cancer.
[11] S. Paik,et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Ruud H. Brakenhoff,et al. Dissecting the metastatic cascade , 2004, Nature Reviews Cancer.
[13] W. Sauerbrei,et al. Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.
[14] A. Seidman. Neoadjuvant Versus Adjuvant Systemic Treatment in Breast Cancer: A Meta-Analysis , 2006 .
[15] L. Kiesel,et al. HER 2-Positive CirculatingTumor Cells Indicate Poor Clinical Outcome in Stage I to III Breast Cancer Patients , 2006 .
[16] Leon W M M Terstappen,et al. Statistical considerations for enumeration of circulating tumor cells , 2007, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[17] A. Schneeweiss,et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] R. Eils,et al. Systemic spread is an early step in breast cancer. , 2008, Cancer cell.
[19] T. Fehm,et al. A pooled analysis of bone marrow micrometastasis in breast cancer. , 2005, The New England journal of medicine.
[20] Dieter Lutz,et al. Tumor cell detection in peripheral blood and bone marrow , 2006, Current opinion in oncology.
[21] T. Fehm,et al. A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation , 2006, Cancer.
[22] G Kvalheim,et al. Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] A. Vincent-Salomon,et al. A “class action” against the microenvironment: do cancer cells cooperate in metastasis? , 2008, Cancer and Metastasis Reviews.
[24] Hellmut Samonigg,et al. Comparison of two methods for enumerating circulating tumor cells in carcinoma patients , 2005, Cytometry. Part B, Clinical cytometry.
[25] J. Ioannidis,et al. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. , 2005, Journal of the National Cancer Institute.
[26] Funda Meric-Bernstam,et al. HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer , 2009, Breast Cancer Research and Treatment.
[27] Robin L. Jones,et al. Neoadjuvant treatment for early-stage breast cancer: opportunities to assess tumour response. , 2006, The Lancet. Oncology.
[28] Leon W.M.M. Terstappen,et al. Circulating Tumor Cells versus Imaging—Predicting Overall Survival in Metastatic Breast Cancer , 2006, Clinical Cancer Research.
[29] C. Sotiriou,et al. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] M. Untch,et al. The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[31] H Sommer,et al. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] D. Wickerham,et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] Alison Stopeck,et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.
[34] Thomas Rau,et al. Circulating Tumor Cells in Breast Cancer: Correlation to Bone Marrow Micrometastases, Heterogeneous Response to Systemic Therapy and Low Proliferative Activity , 2005, Clinical Cancer Research.
[35] Selin Carkaci,et al. Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings , 2008, Breast Cancer Research and Treatment.
[36] G. Hortobagyi,et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] Christos Hatzis,et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] R. Eils,et al. From latent disseminated cells to overt metastasis: Genetic analysis of systemic breast cancer progression , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[39] T. Fehm,et al. Primary systemic therapy does not eradicate disseminated tumor cells in breast cancer patients , 2007, Breast Cancer Research and Treatment.
[40] T. Kroll,et al. Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] T. Fehm,et al. Presence of apoptotic and nonapoptotic disseminated tumor cells reflects the response to neoadjuvant systemic therapy in breast cancer , 2006, Breast Cancer Research.
[42] L. Kiesel,et al. HER2-Positive Circulating Tumor Cells Indicate Poor Clinical Outcome in Stage I to III Breast Cancer Patients , 2006, Clinical Cancer Research.
[43] S. Braun,et al. The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence , 2005, Cancer.
[44] Alison Stopeck,et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] Tanja Fehm,et al. HER-2 gene amplification can be acquired as breast cancer progresses. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[46] A. Vincent-Salomon,et al. Bone marrow micrometastasis in breast cancer: review of detection methods, prognostic impact and biological issues , 2007, Journal of Clinical Pathology.
[47] J. Nesland,et al. Isolated Tumor Cells in Bone Marrow Three Years after Diagnosis in Disease-Free Breast Cancer Patients Predict Unfavorable Clinical Outcome1 , 2004, Clinical Cancer Research.
[48] R. Coombes,et al. The clinical significance of disseminated tumor cells in breast cancer , 2007, Nature Clinical Practice Oncology.
[49] K. Pienta,et al. Global gene expression profiling of circulating tumor cells. , 2005, Cancer research.
[50] J. Mendelsohn,et al. Circulating tumor cells in breast cancer: Advanced tools for “tailored” therapy? , 2006, Proceedings of the National Academy of Sciences.
[51] G. Hortobagyi,et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] D. Mavroudis,et al. Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.